Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.58 |
| ▸ | PNMT | P11086 | 2/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.46 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10128 | 1.00 | IDO1 (0.58) | IDO1PNMTTAAR1SIGMAR1CYP4F2 | |
| SCHEMBL1964765 | 0.97 | IDO1 (0.56) | IDO1PNMTTAAR1SIGMAR1CYP4F2 | |
| SCHEMBL27276965 | 0.91 | TP53 (0.61) | IDO1PNMTTAAR1SIGMAR1CYP4F2 | |
| SCHEMBL4962307 | 0.82 | SIGMAR1 (0.45) | IDO1PNMTTAAR1SIGMAR1POLB | |
| SCHEMBL30019331 | 0.80 | PNMT (0.61) | IDO1PNMTTAAR1SIGMAR1IGF1R | |
| SCHEMBL30488129 | 0.80 | CYP4F2 (0.43) | IDO1PNMTTAAR1SIGMAR1CYP4F2 | |
| SCHEMBL507167 | 0.80 | CYP4F2 (0.43) | IDO1PNMTTAAR1SIGMAR1CYP4F2 | |
| SCHEMBL30595364 | 0.80 | CYP4F2 (0.40) | IDO1PNMTTAAR1CYP4F2CYP4A11 | |
| SCHEMBL177296 | 0.80 | PNMT (0.61) | IDO1PNMTTAAR1SIGMAR1IGF1R | |
| SCHEMBL507688 | 0.80 | CYP4F2 (0.40) | IDO1PNMTTAAR1CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080069-A | Phospholipid compounds and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122055361-A | Fascin inhibitors | 北京双鹤润创科技有限公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4720054-A1 | FASCIN INHIBITORS | Beijing Double-Crane Runchuang Technology Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| WO-2025129168-A1 | TRIAZOLONE INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE AND THEIR THERAPEUTIC USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-06-19 | — | — | WO | disclosed |
| EP-4562015-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| CN-119977904-A | Benzoxy (carbon/sulfur) azepine compound and application thereof in medicine | 合肥工业大学 | 2025-05-13 | — | — | CN | disclosed |
| CN-119343339-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2025-01-21 | — | — | CN | disclosed |
| CN-114524776-B | Tetrazole compound and application thereof | 中国科学院广州生物医药与健康研究院 | 2024-12-13 | — | — | CN | disclosed |
| EP-4469444-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024240245-A1 | FASCIN INHIBITORS | Beijing Double-Crane Runchuang Technology Co., Ltd. (CN) | 2024-11-28 | — | — | WO | disclosed |
| CN-115772135-A | Triazinone compound and application thereof | 中国科学院广州生物医药与健康研究院 | 2023-03-10 | — | — | CN | disclosed |
| CN-115461056-A | Novel lymphoid specific tyrosine phosphatase (LYP) inhibitors | 普渡研究基金会 | 2022-12-09 | — | — | CN | disclosed |
| CN-110023292-B | Apoptosis inhibitors | 北京生命科学研究所 | 2022-10-04 | — | — | CN | disclosed |
| CN-114957246-A | 5,6,7, 8-tetrahydropyrido [4,3-d ] pyrimidin-4 (3H) -one derivatives and application thereof | 苏州恩华生物医药科技有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-111148746-B | Heterocyclic compounds | 武田药品工业株式会社 | 2022-08-05 | — | — | CN | disclosed |
| CN-114524776-A | Tetrazole compound and application thereof | 中国科学院广州生物医药与健康研究院 | 2022-05-24 | — | — | CN | disclosed |
| US-11319321-B2 | [1,2,4]triazolo[1,5-a]pyrimidine compounds as PDE2 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-03 | — | — | US | disclosed |
| CN-114174273-A | Compounds and uses thereof | 优曼尼蒂治疗公司 | 2022-03-11 | — | — | CN | disclosed |
| WO-2022046631-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022042691-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319321-B2 | [1,2,4]triazolo[1,5-a]pyrimidine compounds as PDE2 inhibitors | PDE2A, PDE12, PDE5A | IDO1 311/4885PNMT 259/4885TAAR1 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.